Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 6

Tiny brain probe reveals how deep-brain neurons can be measured and manipulated

A new breakthrough technology, co-developed by UCL scientists, that simultaneously records and manipulates neuron activity deep within the brain could transform our understanding of neural circuits and neurological conditions, such as Alzheimer’s disease and schizophrenia.

The device, known as Neuropixels Opto and researched in mice, integrates two powerful but traditionally separate techniques—electrophysiology (the study of the electrical activity of living cells) and optogenetics (combining genetics and optics to control cells). They form a single probe, enabling unprecedented insight into how individual neurons in the brain function and interact.

Published in Nature Methods, the system allows researchers to monitor the electrical activity of hundreds of neurons while also selectively activating or silencing specific cells using light.

Why some tumors resist immunotherapy: Blocking miR-25 may help turn ‘cold’ cancers ‘hot’

Immune checkpoint therapy, a type of cancer immunotherapy that helps the immune system recognize and attack tumors, has transformed cancer treatment. While these therapies can produce long-lasting benefits for some patients, many cancers either fail to respond or become resistant over time.

One major challenge is the tumor microenvironment —the network of cells and signals surrounding tumors that can weaken immune cells and protect cancer from treatment. This protective environment can act like a shield that prevents immunotherapy from working effectively.

Researchers at University of California San Diego investigated whether microRNAs —small RNA molecules that help control gene activity—play a role in creating this treatment-resistant environment. The team focused on microRNA-25 (miR-25), which stood out after analyses showed that its levels changed in tumors that responded to immunotherapy.

Targeted therapy reduces risk of lung cancer recurrence by 83% in rare genetic subtype

A new study co-led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center shows that the targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype of early-stage non-small cell lung cancer (NSCLC), potentially offering a new treatment option to help keep the disease from coming back after standard therapy.

The international phase 3 clinical trial, called LIBRETTO-432, found that after two years, 92% of patients with stage II–IIIA RET fusion-positive NSCLC who received selpercatinib after standard treatment were alive without their cancer returning—a measure known as event-free survival—compared with 61% of patients who received a placebo. Overall, the treatment reduced the risk of cancer recurrence or death by 83%.

The results were shared during the Plenary Session on May 31 at the American Society of Clinical Oncology Annual Meeting by Dr. Jonathan Goldman, Health Sciences Clinical Professor in the Department of Medicine at the David Geffen School of Medicine at UCLA. The paper was also published in the New England Journal of Medicine.

Children’s brain tumors may spread faster when microglia build invasion-friendly scaffolding

Researchers at the Institute of Environmental Medicine (IMM), Karolinska Institutet, have identified a possible mechanism behind the spread of the aggressive brain tumor diffuse midline glioma. The study shows that the brain’s own immune cells, microglia, may contribute to the tumor’s invasive capacity by producing the protein fibronectin. The results are published in the journal Cell Death & Disease.

Diffuse midline glioma (DMG), also known as diffuse intrinsic pontine glioma (DIPG), is a rare but highly aggressive brain tumor that primarily affects children. There is currently no effective treatment, and the prognosis is very poor.

In the present study, the researchers investigated how microglia—the brain’s immune cells—are affected by tumor cells and what role they play in disease progression.

Scientists discover inherited traits that break Mendel’s Laws of genetics

A major mouse study found that some inherited traits are passed down through epigenetic changes that break the classic rules of genetics. Researchers discovered hundreds of cases where these chemical DNA marks behaved unexpectedly, including some that seemed to emerge out of nowhere. They also identified the first known naturally occurring paramutation in a mammal, hinting that environmental influences may play a larger role in inheritance than scientists realized.

For real heart protection, the weekly exercise number climbs far beyond current advice

Adults should aim to do between 560 and 610 minutes a week of moderate to vigorous physical activity to achieve a substantial reduction in the risk of heart attacks and stroke, suggest the findings of an observational study published in the British Journal of Sports Medicine.

This is between three to four times higher than the current public health recommendation that adults do at least 150 minutes a week of moderate to vigorous physical exercise such as brisk walking, running, or cycling.

People who are less fit need to do slightly more exercise than those who are very fit to get the same cardiovascular benefits, the study suggests.

Therapeutic effects of selumetinib on diffuse neurofibroma and optic pathway glioma in neurofibromatosis type 1

Selumetinib is approved for the treatment of inoperable plexiform neurofibromas (PN) in patients with neurofibromatosis type 1 (NF1). However, its efficacy in treating NF1-associated diffuse neurofibromas (NF1-DN) or optic pathway gliomas (NF1-OPG) remains unclear. We evaluated the efficacy and safety of selumetinib in these subgroups.

This was a sub-analysis of a Korean phase II open-label trial focusing on non-target treatment effects on NF1-DN and NF1-OPG. A total of 88 pediatric and adult patients with NF1-PN (59 children and 29 adults) in this trial had been treated for at least 2 years (~ 26 cycles, 28-day cycle) with oral selumetinib (20 or 25 mg/m², or 50 mg/dose every 12 h). Tumor volume, quality of life (QoL), and visual acuity were assessed.

Among the 88 included patients, NF1-DN was diagnosed in 25 (28%), and NF1-OPG in 3 (3%). All NF1-DN patients exhibited disfigurement, two experienced pain, and a partial response (PR; ≥20% tumor reduction at a single time) was achieved in 9 of these cases (36%). The median time to PR was 6 cycles (range, 6–12), and the median time to best response was 18 cycles (range, 6–26), with a median volume change of − 11.9% (range, − 55.4% to + 36.3%). Confirmed PR (cPR; PR sustained for 6 cycles) was observed in 6 NF1-DN patients (24%), stable disease (SD) was observed in 9 of these patients (36%), and progressive disease (PD) in 10 cases (40%). In a paired comparison, cPR was significantly lower for NF1-DN than for NF1-PN (24% vs. 88%, P 0.001), and the median best volume reduction was also smaller (− 11.9% vs. −42.1%, P 0.001). For the 3 NF1-OPG patients, visual impairment was present in all cases at baseline. One patient achieved PR at cycle 12 (− 36.

New 3D map of the heart’s electrical wiring can help patients with congenital heart disease

Researchers from UCL (University College London) and the ESRF (The European Synchrotron) have produced the first three-dimensional map of the heart’s electrical wiring in Tetralogy of Fallot, one of the most common congenital heart problems, revealing anatomical features that may explain why many patients develop heart conduction disorders in this condition.

The research, part of the Human Organ Atlas international collaboration, can be used for surgical training and lead to even better outcomes for patients. The research appears in JTCVS Structural and Endovascular.

Congenital heart disease affects around 1% of the population worldwide. In many cases, babies must undergo life-saving heart surgery shortly after birth. Although survival rates are now high, many patients develop complications later in life, particularly abnormal heart rhythms or contraction patterns. Surgeons have long known that these problems can arise when the heart’s delicate electrical conduction system, which is invisible during surgery, is disturbed.

Fiber optic components enable high-performance 2-µm fiber lasers

Laser systems operating in the 2-micrometer wavelength range open diverse opportunities in medical technology, agriculture, and plastics processing. In the Eurostars project DECOMP, Laser Zentrum Hannover e. V. (LZH) has developed novel fiber optic components that overcome previous technical barriers.

Thulium-doped fiber lasers operate at a wavelength of approximately 2 micrometers, making them particularly well-suited for applications where conventional lasers reach their limits. However, commercially available laser sources that simultaneously offer high beam quality, sufficient laser power, and the necessary reliability in quasi-continuous-wave operation at power levels around 1 kilowatt have been lacking.

In the project, LZH scientists developed novel fiber optic components based on triple-clad fibers that enable a reliable and low-maintenance laser architecture. For the implementation of the final laser system, LZH collaborated with Futonics Laser GmbH as well as South Korean partners COSET, inc. and the Korean Photonics Technology Institute.

/* */